Copulation of Ixodes ricinus males and females on the host and its potential impact on pathogen transmission

Occurrence of Ticks and Tick-Borne Pathogens During Warm Winter-A Snapshot from Central Europe

BACKGROUND

Climate warming and anthropogenic environmental changes impact the spread of ticks and tick-borne pathogens (TBPs). This study investigated the occurrence of ticks and the risk of TBPs infection in urban and rural recreational areas in Eastern Poland at record-high temperatures in winter.

METHODS

Ticks were collected from vegetation using the flagging method. Various types of polymerase chain reactions were applied to detect Borrelia burgdorferi s.l., Anaplasma phagocytophilum, Rickettsia spp., and Babesia spp. in the studied ticks.

RESULTS

268 ticks were sampled in the four urban/suburban and one rural sites, including 78 Ixodes ricinus specimens and 190 Dermacentor reticulatus ticks. Of the ticks, 49.19% were infected by at least one TBP, including 41.03% of I. ricinus and 63.04% of D. reticulatus specimens. Co-infections with TBPs that involved only I. ricinus were recorded in 6.41% of these ticks.

CONCLUSIONS

The study indicates that hosts are exposed to tick attacks and TBPs infection in Central Europe at high temperatures in winter. The high activity of ticks may increase the incidence of tick-borne diseases in humans and companion animals. The record's importance indicates that practical preventive measures against TBPs should be taken due to weather conditions rather than the season.

Clinical efficacy and safety of a single administration of fluralaner injectable suspension (BRAVECTO® injectable) vs. monthly administration of oral afoxolaner (NexGard®) in dogs for tick and flea control over one year under European field conditions

BACKGROUND

Year-round control of canine flea and tick infestations requires owner compliance with recommendations for regular treatments. Compliance failures can result in increased exposure of dogs to tick-borne pathogens and resurgence of flea populations. This study investigated the year-long efficacy of fluralaner 150 mg/ml injectable suspension (BRAVECTO® injectable), developed to remove the need for multiple owner-administered, within-year treatments.

METHODS

This randomized, examiner-masked, non-inferiority study enrolled household dogs at veterinary clinics in Germany, France, and Spain. Each household contained a primary dog infested with ≥ 4 ticks or ≥ 5 fleas. Additional dogs in each household received the same treatment as the primary dog, either a single injection with fluralaner (15 mg/kg) on day 0, or 12 monthly treatments with oral afoxolaner (NexGard®) beginning on day 0. Owners presented their dogs for tick and flea assessments at visits 2 through 10 (days 14, 28, 56, 84, 112, 224, 280, 336, 365). Primary endpoints were the percentages of primary dogs free of live ticks or fleas at visit 10. Secondary endpoints were the percentage reductions of live ticks and fleas in primary dogs. All treated dogs were observed for adverse reactions throughout the study.

RESULTS

The analyzed per-protocol population included 415 primary dogs (fluralaner 279, afoxolaner 136) from 976 treated dogs (fluralaner 653, afoxolaner 323). From visits 2 through 10, ≥ 95% of primary dogs in each group were tick-free, and ≥ 93% were flea-free. The percentage of dogs free of ticks or fleas was non-inferior (P ≤ 0.0048) in the fluralaner group compared to the afoxolaner group at visit 10 and all earlier visits. Compared to baseline, fluralaner-group tick and flea counts were reduced by > 99%; afoxolaner-group tick and flea counts by > 98% and > 97%, respectively. There were no unexpected adverse events in any treated dog in either group, nor any sign of interactions between concomitantly administered vaccines and medications.

CONCLUSIONS

A single subcutaneous fluralaner injection provided a level of tick and flea control equivalent to that of 12 monthly administrations of afoxolaner. The sustained fluralaner efficacy helps maintain canine health by retaining treatment with the veterinarian and eliminating treatment-compliance failures by pet owners between veterinary visits.